Alimentary Pharmacology & Therapeutics最新文献

{"title":"The Lipidomic Profile Discriminates Between MASLD and MetALD","authors":"Kai Markus Schneider, Feng Cao, Helen Ye Rim Huang, Lanlan Chen, Yazhou Chen, Rongpeng Gong, Anastasia Raptis, Kate Townsend Creasy, Jan Clusmann, Felix van Haag, Paul-Henry Koop, Adrien Guillot, Tom Luedde, Rohit Loomba, Sven Francque, Carolin Victoria Schneider","doi":"10.1111/apt.70012","DOIUrl":"https://doi.org/10.1111/apt.70012","url":null,"abstract":"The recent consensus statement redefined steatotic liver diseases. Metabolic dysfunction-associated steatotic liver disease (MASLD) and metabolic dysfunction and alcohol-related liver disease (MetALD) now represent distinct disease entities. However, biomarkers that differentiate MASLD and MetALD remain largely unknown.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"160 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143393562","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Antibiotic Use and Risk of Microscopic Colitis in Older Adults: A Nationwide Self-Controlled Case Series Study","authors":"Máté Szilcz, Jonas W. Wastesson, David Bergman, Kristina Johnell, Jonas F. Ludvigsson","doi":"10.1111/apt.70028","DOIUrl":"https://doi.org/10.1111/apt.70028","url":null,"abstract":"Several drugs have been linked to the risk of microscopic colitis (MC), a condition characterised by watery, non-bloody diarrhoea. Antibiotics can induce similar symptoms, but their connection to MC remains unclear.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"78 5 Pt 1 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-02-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143393564","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Upadacitinib for Induction of Remission in Paediatric Crohn's Disease: An International Multicentre Retrospective Study","authors":"Shlomi Cohen, Elizabeth A. Spencer, Michael T. Dolinger, David L. Suskind, Katarina Mitrova, Ondrej Hradsky, Máire A. Conrad, Judith R. Kelsen, Holm H. Uhlig, Christos Tzivinikos, Paul Henderson, Magdalena Wlazlo, Lukas Hackl, Dror S. Shouval, Matteo Bramuzzo, Darja Urlep, Christine Olbjørn, Giulia D'Arcangelo, Gemma Pujol-Muncunill, Dotan Yogev, Ben Kang, Marco Gasparetto, Christine Rungoe, Kaija-Leena Kolho, Iva Hojsak, Lorenzo Norsa, Firas Rinawi, Naire Sansotta, Ramit Magen Rimon, Maya Granot, Luca Scarallo, Eunice Trindade, Marta Velasco Rodríguez-Belvís, Dan Turner, Anat Yerushalmy-Feler","doi":"10.1111/apt.70016","DOIUrl":"https://doi.org/10.1111/apt.70016","url":null,"abstract":"There are scarce data available on upadacitinib in children with Crohn's disease (CD).","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"15 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-02-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk of Hepatocellular Cancer in U.S. Patients With Compensated Cirrhosis Treated With Direct-Acting Antivirals Versus Interferon","authors":"Hashem B. El-Serag, Hao Duong, Michelle Luster, Fasiha Kanwal, Deanna D. Hill, Margaret Burroughs, Candido Hernandez, Barbara A. Haber, Lois M. Larsen, John F. Marcinak, Lani R. Wegrzyn, Jennifer R. Kramer","doi":"10.1111/apt.18525","DOIUrl":"https://doi.org/10.1111/apt.18525","url":null,"abstract":"Few studies have examined the risk of de novo hepatocellular carcinoma (HCC) among hepatitis C virus (HCV)–infected patients with cirrhosis who received interferon (IFN)-free direct-acting antiviral (DAA) therapy relative to patients who received IFN-containing therapy or remained untreated.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"17 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-02-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143371566","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Optimising Prevention of Adverse Events and Antiviral Prophylaxis for HBV-Infected HCC Patients Undergoing Immunotherapy","authors":"Jialing Wang, Wenjun Meng","doi":"10.1111/apt.18481","DOIUrl":"10.1111/apt.18481","url":null,"abstract":"<p>We have perused with intrigue the original article by Hung et al., which appraises the efficacy of nucleos/tide analogue (NUC) prophylaxis for downgrading the HBV reactivation (HBVr) in patients with hepatocellular carcinoma (HCC) receiving immunotherapies [<span>1</span>]. Besides, the study emphasised that abnormal baseline alanine aminotransferase (ALT) levels can be identified as a significant risk factor for hepatic adverse events during immune checkpoint inhibitor (ICI) therapy. The study underscores the importance of monitoring liver function and considering antiviral prophylaxis in HBV-infected HCC patients receiving ICI therapy to mitigate hepatic complications.</p><p>In the current study, only hepatic immune-related adverse events (irAEs) were analysed. As a result, the impact of different ICIs on the incidence of hepatic irAEs is still unclear. At present, clinicians' understanding of irAEs is mostly limited to traditional single-organ irAEs. Multi-organ irAEs (MO-irAEs), which means two or more organs involved, are usually accompanied by more serious security risks, requiring more active prevention and handling [<span>2</span>]. Among all patients with irAEs, the incidence of MO-irAEs in dual-immunotherapy (programmed cell death protein 1 [PD-1] or programmed death-ligand 1 [PD-L1] inhibitor plus cytotoxic T-lymphocyte-associated protein 4 [CTLA-4] inhibitor) was 35.9%, higher than 22.6% in CTLA-4 inhibitor monotherapy and 17.2% in PD-1/PD-L1 inhibitor monotherapy [<span>3</span>]. The liver is also one of the most involved organ in MO-irAEs, following thyroid, skin and lung [<span>3</span>]. However, no therapeutic approaches regarding immune-related hepatitis were mentioned in the current study. When irAEs occur, immunomodulators with autotoxicity spectra that overlap with ICIs should be avoided. Patients with liver damage due to immune-related hepatitis should be prudent to use immunomodulators with hepatotoxicity like infliximab [<span>4</span>].</p><p>In this study, there is a lack of description in the NUC prophylaxis use in different status of HBV markers, which may result in outcome bias. Studies show that even previous use of NUCs followed by discontinuation of the drug can also result in a higher rate of HBV relapse [<span>5</span>]. Recently, a study verified that switching from NUC to pegylated interferon alpha-2a (PegIFN-α-2a) significantly reduces virological relapse rates and results in higher HBsAg clearance compared with discontinuation of NUC alone [<span>5</span>]. In the future, the exploration of the immunological mechanisms underlying the benefits of PegIFN-α-2a and its integration into routine clinical practice, especially for patients with low baseline HBsAg levels, will further support its clinical application.</p><p>In conclusion, Hung et al.'s work provides a valuable contribution to our comprehension of the adverse event management of HCC patients undergoing ICI immunotherapy. Implementing antiviral prop","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 5","pages":"925-926"},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18481","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124387","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Refining the Understanding of Hepatic Steatosis and Cardiovascular Risk—Addressing Key Variables and Subgroup Analyses","authors":"Changhu Sun, Zeping Chen, Lincheng Duan","doi":"10.1111/apt.18445","DOIUrl":"10.1111/apt.18445","url":null,"abstract":"<p>We have carefully reviewed the recently published article, ‘Coronary Artery Disease and Major Adverse Cardiovascular Events in People With Hepatic Steatosis at Low Atherosclerotic Cardiovascular Disease Risk’ [<span>1</span>]. This study highlights the critical role of hepatic steatosis (HS) as a cardiovascular risk enhancer, particularly in individuals traditionally considered to have low-to-intermediate atherosclerotic cardiovascular disease (ASCVD) risk. Although we commend the authors for their valuable contribution, we would like to offer several perspectives and suggestions for further consideration.</p><p>First, although the study accounted for traditional cardiovascular risk factors, the absence of lifestyle-related variables may limit the accuracy of the findings. For example, high-fat, high-sugar diets and sedentary behaviours could exacerbate systemic inflammation and metabolic dysregulation, thereby worsening cardiovascular outcomes in HS patients [<span>2, 3</span>]. Additionally, socioeconomic status (SES) may influence the relationship between HS and ASCVD risk through pathways such as healthcare access, medication adherence and health behaviours [<span>4, 5</span>]. The omission of these key factors may overestimate or underestimate the true impact of HS on cardiovascular risk.</p><p>Second, while the study performed stratified analyses on the basis of ASCVD risk and HS status, further subgroup analyses could reveal more nuanced risk profiles. For instance, sex and age may play distinct roles in the association between HS and cardiovascular disease. Existing research indicates significant sex-based differences in inflammatory responses, lipid metabolism and cardiovascular disease mechanisms [<span>6</span>]. Conducting sex-specific analyses could uncover the unique effects of HS in males and females [<span>7</span>]. Similarly, age is a critical variable, as cardiovascular risk and HS characteristics may differ across age groups (e.g., < 50 years, 50–65 years and > 65 years) [<span>8</span>]. Younger patients, for instance, might have a longer latency period before developing clinical cardiovascular events. Such analyses would facilitate the development of more targeted intervention strategies for different demographic groups.</p><p>Furthermore, obesity and metabolic dysregulation, as key risk factors for HS [<span>9</span>], are also pivotal drivers of cardiovascular disease [<span>10</span>]. Future research could stratify patients by body mass index (BMI) or metabolic syndrome status to explore differences in the impact of HS on cardiovascular events across weight categories. For example, comparing the effects of HS in normal-weight, overweight and obese patients may help determine whether BMI acts as a mediator in the relationship between HS and cardiovascular risk. This could clarify the independent contribution of obesity to the HS–cardiovascular disease association.</p><p>Lastly, the potential impact of medication ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 5","pages":"933-934"},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18445","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124388","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial on ‘Early HBcrAg and Anti-HBc Levels Identify Patients at High Risk for Severe Flares After Nucleos(t)ide Analogue Cessation: A Pooled Analysis of Two Clinical Trials’","authors":"Ming Chao Tsai, Tsung Hui Hu","doi":"10.1111/apt.18447","DOIUrl":"10.1111/apt.18447","url":null,"abstract":"<p>Cessation of nucleos(t)ide analogue (NA) can lead to the restoration of the immune system and ultimately result in higher rates of functional cure in a selected group of patients with chronic hepatitis B (CHB). However, off-treatment viral relapse is common and may lead to hepatic flares, hepatic decompensation or even death [<span>1-3</span>]. Consequently, identifying biomarkers and high-risk patient characteristics is important.</p><p>The manuscript by Dongelmans et al. highlights that higher HBcrAg levels, lower anti-HBc levels and a higher hepatitis B core-related antigen (HBcrAg) over hepatitis B core antibody (anti-HBc) ratio at the end of treatment (EOT) can predict severe flares (alanine aminotransferase [ALT] ≥ 10× upper limit of normal [ULN]) following NA cessation [<span>4</span>]. Most previous studies on relapse after treatment cessation have been retrospective, focusing primarily on hepatitis B surface antigen (HBsAg) and hepatitis B virus (HBV) DNA analysis [<span>1</span>]. Even though recent studies have examined HBcrAg and anti-HBc, these markers have generally been studied separately and rarely analysed together [<span>5, 6</span>]. Additionally, most studies have focused only on EOT as the primary analysis point. This study is the first to simultaneously analyse HBsAg, HBV DNA, HBcrAg and anti-HBc to investigate severe flares after treatment cessation. Pooling data from two prospective studies [<span>7, 8</span>] showed that higher HBcrAg, lower anti-HBc and a higher HBcrAg/anti-HBc ratio at EOT and at 6 weeks off-treatment are associated with severe flares after NA withdrawal. As HBcrAg provides more direct evidence of HBV replication and can be detected in clinical cases, where serum HBV DNA is undetectable during NA therapy, and as anti-HBc reflects certain aspects of the host's antiviral immune response [<span>9</span>], the combination of these two markers offers a more accurate reflection of the host–virus interaction. Importantly, the main reason why authors have chosen the Weeks 6–8 time point was because most flares occurred early after NA withdrawal (median time of 12 weeks) [<span>1-3</span>]. Early risk stratification is therefore essential. Based on the HBV kinetics they reported, significant changes from EOT were observed beyond off-treatment Week 4, which is why the first subsequent assessment was used for outcome prediction.</p><p>Nevertheless, some points merit further attention. In the present study, severe flares were observed in 28% of patients, which is unusually higher than the prior studies [<span>1-3, 5, 6</span>]. The study by Dongelmans et al. combines data from two prospective studies, reflecting more realistic clinical significance, as retrospective studies may underestimate the exact figures. However, nearly 70% of patients were treated with tenofovir disoproxil fumarate (TDF) or tenofovir alafenamide fumarate (TAF) in this study. As TDF is associated with faster and more pronounced post-cessat","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 5","pages":"907-908"},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18447","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143125002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Letter: Enhancing the Analysis and Clinical Applicability of Ferritin as a Biomarker for MASLD in Type 2 Diabetes Patient","authors":"Pengfei Xi, Hai Li, Shengxian Li","doi":"10.1111/apt.18417","DOIUrl":"10.1111/apt.18417","url":null,"abstract":"<p>We were very interested to read the article by Amangurbanova et al. published in the <i>Journal</i> [<span>1</span>]. This study provides valuable insights into the association between hyperferritinaemia and metabolic dysfunction-associated steatotic liver disease (MASLD), as well as hepatic fibrosis, in patients with type 2 diabetes mellitus (T2DM). In addition to the limitations the authors mentioned, we believe that additional analytical approaches could enhance the depth of the findings and support future research directions.</p><p>First, refining subgroup analyses using continuous ferritin data and additional patient characteristics could provide more precise insights. Specifically, stratifying patients based on disease duration, glycaemic control levels (e.g., HbA1c) and body mass index (BMI) might reveal different risk levels within T2DM populations [<span>2</span>]. Ethnic background is another important factor to analyse, as iron metabolism, MASLD progression and inflammatory responses can vary significantly across ethnic groups. Additionally, subgroup analyses considering medication history, such as long-term use of statins or insulin, may identify unique risk profiles. Such analyses could ultimately inform more individualised treatment strategies.</p><p>Second, although logistic regression was used to assess the ferritin-MASLD relationship, more flexible statistical models might better capture complex interactions between variables. Mixed-effects models could account for multi-level data structures, such as data from different healthcare settings, and machine learning methods like random forests might uncover non-linear relationships and interactions that traditional models might miss [<span>3</span>]. Furthermore, to better understand ferritin's independent role in MASLD progression, methods like propensity score matching or structural equation modelling could help clarify causal relationships [<span>4</span>].</p><p>Including inflammatory and oxidative stress biomarkers may help elucidate MASLD's pathological mechanisms [<span>5</span>]. Besides high-sensitivity C-reactive protein (hs-CRP) [<span>6</span>], oxidative stress markers like 8-iso-prostaglandin F2α [<span>7</span>] could help assess how ferritin levels influence MASLD development. Such markers would provide a clearer view of how iron overload, chronic inflammation and MASLD interrelate, and potentially offer a more sensitive biomarker panel for identifying high-risk patients.</p><p>Last, from a clinical perspective, the potential of ferritin as a stratification and dynamic monitoring tool for MASLD deserves further exploration. Monitoring changes in ferritin alongside liver stiffness or hepatic fat content (via MRI or ultrasound elastography) could enhance ferritin's clinical utility. Future studies might also examine how interventions (e.g., dietary modifications and iron chelation therapy) impact MASLD progression in hyperferritinaemic T2DM patients, which could info","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 5","pages":"927-928"},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18417","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124389","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Editorial: Flipping the Script—Higher Risk of Hepatocellular Carcinoma With Tenofovir Compared to Entecavir in a French Population-Based Cohort","authors":"Ariel Lee, Kali Zhou","doi":"10.1111/apt.18499","DOIUrl":"10.1111/apt.18499","url":null,"abstract":"<p>Chronic hepatitis B virus (HBV) infection remains a leading cause of liver disease worldwide, with a risk of progression to cirrhosis and hepatocellular carcinoma (HCC). Currently, nucleoside analogues entecavir (ETV) and tenofovir disoproxil fumarate (TDF) are recommended equally by guidelines as first-line antiviral therapy for chronic HBV and are the most common therapies in high-income countries [<span>1</span>]. For many years now, the comparative efficacy of these therapies remains subject to ongoing clinical investigation [<span>2-6</span>]. In particular, TDF has been suggested to lower the risk for development of HCC compared to ETV in several Asian cohorts [<span>2, 3</span>], while others have reported no difference [<span>4-6</span>].</p><p>Lam et al. provide an alternative perspective in this issue of <i>Alimentary Pharmacology and Therapeutics</i> through retrospective analysis of a real-world population–based French national health insurance database (SNDS) between 2012 and 2021 [<span>7</span>]. The authors nicely demonstrate decreases in excess mortality among chronic HBV patients compared to matched controls over time, corresponding with an uptick in treatment uptake, providing indirect evidence of treatment benefit. However, among 14,054 treatment-naïve patients with chronic HBV, treatment initiation with tenofovir was associated with an increased risk of HCC (but not transplant or death) compared with entecavir (HR, 1.31; 95% CI, 1.07–1.62)—the opposite direction than expected based on prior evidence. There were several methodological strengths: a large sample size sourced from nationwide data, conferring higher statistical power to detect differences, utilising a proven multi-criteria algorithm with a high sensitivity and specificity for viral hepatitis to identify all adult patients with known chronic HBV in France. A new user comparative design, a 6-month lag period, propensity score matching and a negative control were all employed to limit the effect of confounders. Through an <i>E</i>-value calculation, the authors estimate that any unmeasured confounder would need a substantial hazard ratio of 1.9 to ameliorate the observed effect.</p><p>So, is it perhaps that there is something unique about the European population that could explain this inverse result? Of note, no difference was seen in the well-characterised European PAGE-B cohort [<span>8</span>]. A more likely explanation—the one supported by conclusions from meta-analyses on this topic—may be that this cohort, while population-based, remains an administrative cohort rather than a clinical one [<span>9, 10</span>]. The reliance on ICD-10 codes for baseline clinical characteristics, most notably the presence of cirrhosis, is a major limitation. This method fails to incorporate clinical variables such as HBV DNA levels, HBeAg and serum ALT levels to establish HBV infection phase, as well as platelet count and more nuanced fibrosis markers to accurately categorise ","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"61 6","pages":"1055-1056"},"PeriodicalIF":6.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/apt.18499","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143125003","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Crohn's Disease With Latent Tuberculosis Infection or Intestinal Tuberculosis: Rapid Discrimination by Targeted Next-Generation Sequencing","authors":"Lingna Ye, Yushu Cao, Yujuan Fu, Chuwen Tian, Qian Cao","doi":"10.1111/apt.18522","DOIUrl":"https://doi.org/10.1111/apt.18522","url":null,"abstract":"Discriminating Crohn's disease (CD) with latent tuberculosis infection (LTBI) from intestinal tuberculosis (ITB) in tuberculosis-endemic regions remains challenging.","PeriodicalId":121,"journal":{"name":"Alimentary Pharmacology & Therapeutics","volume":"39 1","pages":""},"PeriodicalIF":7.6,"publicationDate":"2025-02-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143124385","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}